The effect of Nrf2 deletion on the proteomic signature in a human colorectal cancer cell line
By: Cheraghi, Omid, Dabirmanesh, Bahareh, Ghazi, Farideh, Amanlou, Massoud, Atabakhshi-kashi, Mona, Fathollahi, Yaghoub, Khajeh, Khosro

BioMed Central
2022-09-13; doi: 10.1186/s12885-022-10055-y

Abstract

Background

Colorectal cancer is one of the most common cancer and the third leading cause of death worldwide. Increased generation of reactive oxygen species (ROS) is observed in many types of cancer cells. Several studies have reported that an increase in ROS production could affect the expression of proteins involved in ROS-scavenging, detoxification and drug resistance. Nuclear factor erythroid 2 related factor 2 (Nrf2) is a known transcription factor for cellular response to oxidative stress. Several researches exhibited that Nrf2 could exert multiple functions and expected to be a promising therapeutic target in many cancers. Here, Nrf2 was knocked down in colorectal cancer cell line HT29 and changes that occurred in signaling pathways and survival mechanisms were evaluated.

Methods

The influence of chemotherapy drugs (doxorubicin and cisplatin), metastasis and cell viability were investigated. To explore the association between specific pathways and viability in HT29-Nrf2, proteomic analysis, realtime PCR and western blotting were performed.

Results

In the absence of Nrf2 (Nrf2), ROS scavenging and detoxification potential were dramatically faded and the HT29-Nrf2 cells became more susceptible to drugs. However, a severe decrease in viability was not observed. Bioinformatic analysis of proteomic data revealed that in Nrf2 cells, proteins involved in detoxification processes, respiratory electron transport chain and mitochondrial-related compartment were down regulated. Furthermore, proteins related to MAPKs, JNK and FOXO pathways were up regulated that possibly helped to overcome the detrimental effect of excessive ROS production.

Conclusions

Our results revealed MAPKs, JNK and FOXO pathways connections in reducing the deleterious effect of Nrf2 deficiency, which can be considered in cancer therapy.







Copyright 2026 InterMDnet | Privacy Policy | Disclaimer | System Requirements